Algeta: Alpharadin treatment more than doubles survival rate in prostate cancer patients
Algeta ASA presents two-year survival data from its Phase II clinical trial with Alpharadin (radium-223) as a treatment for hormone refractory prostate cancer (HRPC).
The new clinical data from the Phase II trial involving 64 HRPC patients shows that more than twice as many patients receiving Alpharadin were alive (10 of 33) two years following treatment compared to those that received placebo (4 of 31).
Previous data from the trial, presented earlier this year at ASCO and in the Lancet Oncology, has also shown that Alpharadin significantly reduces levels of prostate-specific antigen (PSA), a widely recognized biomarker for progression of prostate cancer, and other relevant biomarkers. The treatment regime of four injections of Alpharadin was well tolerated during the 12-week treatment period, and an extended treatment period may further delay disease progression.
Other news from the department research and development
